New developments in the management of hypertension

American Family Physician

Volumn 68, Issue 5, 2003, Pages 853-858+865

  Magill, Michael K ^a   Gunning, Karen ^a   Saffel Shrier, Susan ^a   Gay, Christopher ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; LISINOPRIL; LOSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; NUTRITIONAL STATUS; PRESCRIPTION; REVIEW; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE;

EID: 0041333926     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Woodwell DA. National ambulatory medical care survey: 1996 summary. Adv Data 1997;295:1-25.
2. Kaplan NM. Clinical hypertension. 7th ed. Baltimore: Williams & Wilkins, 1998.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report [Published erratum in JAMA 2003;290:197]. JAMA 2003;289:2560-72.
4. U.S Preventive Services Task Force. Screening: hypertension, 1996. Accessed August 6, 2003, at: www.ahcpr.gov/clinic/uspstf/uspshype.htm.
5. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20.
6. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002;162:577-81.
7. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86 [Published erratum in N Engl J Med 2002;346:544].
8. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens (Greenwich) 2001;3:211-6 [Published erratum in J Clin Hypertens (Greenwich) 2002;4:76].
9. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002;162:582-6.
10. Hermansen K. Diet, blood pressure and hypertension. Br J Nutr 2000;83 Suppl 1:S113-9.
11. Whelton PK, Kumanyika SK, Cook NR, Cutler JA, Borhani NO, Hennekens CH, et al. Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the Trials of Hypertension Prevention. Trials of Hypertension Prevention Collaborative Research Group. Am J Clin Nutr 1997;65(2 Suppl):652S-60S.
12. Griffith LE, Guyatt GH, Cook RJ, Bucher HC, Cook DJ. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated meta-analysis of randomized controlled trials. Am J Hypertens 1999;12(1 Pt 1):84-92.
13. Zemel MB. Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 2001;20(5 Suppl):428S-35S.
14. Cappuccio FP. Sodium, potassium, calcium and magnesium and cardiovascular risk. J Cardiovasc Risk 2000;7:1-3.
15. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
16. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute, 1998. NIH publication no. 98-4083.
17. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
18. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
19. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 1997;278:1745-8.
20. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Arch Intern Med 2001;161:1145-58.
21. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
22. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 2002;39:315-22 [Published erratum in J Am Coll Cardiol 2002;39:1409-10].
23. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97 [Published erratum in JAMA 2003;289:178].
24. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al., for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
25. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALL-HAT Collaborative Research Group. JAMA 2000;283:1967-75 [Published erratum in JAMA 2002;288:2976].
26. American College of Cardiology. Alpha blockers for hypertension. Accessed August 6, 2003, at: www.acc.org/clinical/alerts/alphablockers.htm.
27. Bishop T, Figueredo VM. Hypertensive therapy: attacking the renin-angiotensin system. West J Med 2001;175:119-24.
28. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
29. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised controlled trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
30. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.
31. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
32. Dillon JJ. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 1993;22:798-802.
33. Mogensen CE. Combined high blood pressure and glucose in type 2 diabetes: double jeopardy [Editorial]. BMJ 1998;317:693-4.
34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPD5 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13 [Published erratum in BMJ 1999;318:29].
35. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62 [Published erratum in N Engl J Med 1993;330:152].
36. Weir MR. Diabetes and hypertension: how low should you go and with which drugs? Am J Hypertens 2001;14(5 Pt 2):175-265.
37. Kaplan NM. Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence. Ann Intern Med 2001;135:1079-83.
38. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, for the CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:2091-6.
39. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
40. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
41. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002;287:1003-10.
42. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDIANA Group. Lancet 1999;353:793-6.
43. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study: final results. JAMA 1993;270:713-24.
44. Blacher J, Staessen JA, Girerd X, Gasowski J, Thijs L, Liu L, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
45. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72
46. Cohen JD. Superior physicians and the treatment of hypertension [Editorial]. Arch Intern Med 2002;162:387-8.
47. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
48. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hypertens 1998;16:127-37.
49. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.